Definium says LSD therapy DT120 eased anxiety in second late-stage trial
STAT+: Definium’s LSD therapy eased anxiety in second large trial
Definium Therapeutics said its LSD therapy DT120 helped patients with anxiety in a second late-stage trial。
The reported 5.1-point gap between DT120 and placebo mirrors the company's first late-stage anxiety study, so the pending regulatory filing will test whether that effect size holds up in a review.
Key facts
- Kind of item
- Trial results
- Compound
- LSD
- Condition
- Anxiety
- Source
- STAT: psychedelics (statnews.com)
- Published
- Original
- Read it at statnews.com
How this summary was made
The summary and the “Why it matters” note were written by an AI model from the linked source, and a model scored the item against this site's editorial criteria. The facts above come from the item's topics and from identifiers written out in the stored text. Anything not found there is left out, so a missing row means not stated, not no. Read the original before relying on any detail. Editorial method
Source: STAT: psychedelics · statnews.com
Connected to
- Kind of item
- Trial results
- Compound
- LSD
- Condition
- Anxiety